COVID-19 Vaccination Planning Overview

- Omicron Variant Update
- Vaccination Status
- Clinical Updates
- Pediatric Pfizer Allocation & Ordering Updates
- Storage and Handling Updates
- Other Resources
- Q&A

Last updated: 12/1/2021
Omicron Variant B.1.1.529

- Currently identified in over 30 countries
- Detected 11-9-21 in South Africa
  - First case in San Francisco, returned from South Africa 11/22; mild symptoms; vaccinated but no booster
  - Second case in Minnesota, returned from NYC
- Concerning because of numerous mutations
- Need time to determine transmissibility, severity, and level of protection by current vaccines
- Federal, state and local labs sequencing specimens to identify this variant

Last updated: 12/1/2021
Confirmed & Presumptive Omicron Variant Infections

12/1/21 3:30pm PST

Confirmed & Presumptive Omicron Variant Infections

<table>
<thead>
<tr>
<th></th>
<th>Confirmed</th>
<th>Probable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cases</td>
<td>371</td>
<td>1254</td>
</tr>
<tr>
<td>&gt;=30 countries</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Newsnodes - Omicron tracker

Last updated: 12/1/2021
Mutation Profile

- Multiple mutations associated with **resistance to neutralizing antibodies** (and therapeutic monoclonal antibodies)
- R203K+G204R mutations in nucleocapsid associated with **increased infectivity**
- Cluster of mutations (H655Y + N679K + P681H) adjacent to S1/S2 furin cleavage site — **associated with more efficient cell entry → enhanced transmissibility**
- nsp6 deletion (Δ105-107) — may be associated with **evasion of innate immunity (interferon antagonism) → could also enhance transmissibility**
Santa Clara County
Vaccination Status
SCC COVID-19 Case Rates (12/1/21)

Santa Clara County COVID-19 Cases Dashboard
Last updated on December 1, 2021

Cumulative COVID-19 Cases 151,359
7-Day Rolling Average of New Cases 162

Cases by Specimen Collection Date

Last updated: 12/1/2021
Case Rates by Vaccination Status (12/1/21)

Covid-19 Case Rates by Vaccination Status
Last updated on December 1, 2021

Unvaccinated Case Rate (Ages 12+): 57.0
County Overall Case Rate: 8.4
Fully Vaccinated Case Rate: 5.8

Case Rate per 100,000 residents, 7-day average

Case Rates

- Case Rate for Fully Vaccinated Residents
- Case Rate for Unvaccinated Residents (12+)
- County Overall Case Rate
- Case Rate for Ages 11 and younger

Last updated: 12/1/2021
Doses Administered to Date in SCC (12/1/21)

COVID-19 Vaccinations Among Santa Clara County Residents

Percent of Residents Ages 12+ With Completed Vaccination: 90.4%
Percent of Residents Ages 5+ With Completed Vaccination: 82.7%
Percent of Residents All Ages With Completed Vaccination: 77.7%
Residents All Ages With Completed Vaccination: 1,497,242
Number of Residents with Booster Dose: 404,171

Displaying: Cumulative Doses, Vaccinations by Day, Demographics: Residents All Ages, Demographics: Select Age Group

COVID-19 Vaccine Doses Administered Over Time

Last updated: 12/1/2021
Doses Administered to Date in SCC (12/1/21)

34.7% 58,203 doses

COVID-19 Vaccinations Among Santa Clara County Residents

Residents All Ages with at least One Dose: 1,622,645
84.2% of Residents with at least One Dose

Residents All Ages with Completed Vaccination: 1,497,242
77.7% of Residents with Completed Vaccination

Last updated: 12/1/2021
Number of People Eligible for or Received Booster by Age

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Eligible for Booster Dose</th>
<th>Received Booster Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-29</td>
<td>204604</td>
<td>30254</td>
</tr>
<tr>
<td>30-39</td>
<td>226894</td>
<td>50541</td>
</tr>
<tr>
<td>40-49</td>
<td>210524</td>
<td>59251</td>
</tr>
<tr>
<td>50-64</td>
<td>308785</td>
<td>108423</td>
</tr>
<tr>
<td>65+</td>
<td>257845</td>
<td>143679</td>
</tr>
</tbody>
</table>

Source: 1) California Immunization Registry (CAIR2), data are preliminary as of 11/30/2021
Clinical Updates
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/17/21</td>
<td>Pfizer requests EUA for Paxlovid (FDA meeting pending)</td>
</tr>
<tr>
<td>11/19/21</td>
<td>ACIP/CDC recommends Pfizer and Moderna booster doses for all 18+ yo</td>
</tr>
<tr>
<td>12/2-12/3*</td>
<td>FDA to authorize Merck's molnupiravir [delayed]</td>
</tr>
<tr>
<td>11/18/21</td>
<td>FDA authorizes Pfizer and Moderna booster doses for all 18+ yo</td>
</tr>
<tr>
<td>11/30/21</td>
<td>FDA advisory committee votes to authorize Merck's molnupiravir</td>
</tr>
<tr>
<td>12/2021*</td>
<td>FDA to authorize Pfizer booster doses for 16-17 year olds</td>
</tr>
<tr>
<td>1/2022*</td>
<td>FDA reviews EUA for Moderna 12-17 yo [delayed]</td>
</tr>
<tr>
<td>2022*</td>
<td>FDA Authorization for Pfizer for 2-5 yo, 6 month- 2 yo</td>
</tr>
<tr>
<td>2022(?)*</td>
<td>Moderna submits data for 6-11 yo EUA [delayed]</td>
</tr>
</tbody>
</table>

*Dates subject to change
Molnupiravir – COVID-19 Oral Antiviral

Formulation

- Oral antiviral medication
- 800 mg twice daily x 5 days

Indication

- For treatment of mild to moderate COVID-19 in adults who are at high risk for progressing to severe COVID-19 within 5 days of symptom onset

Emergency Use Authorization (EUA)

- The FDA advisory committee narrowly (13-10) voted to authorize the drug on 11/30/21. Overall efficacy only 30%
- Official FDA authorization and EUA still pending
- Major questions to be addressed around pregnant patients

Last updated: 12/1/2021
Molnupiravir, Continued

Criteria for Use [Pending EUA]

• ≥ 18 years old
• COVID-19 positive test (PCR or antigen test)
• Initial onset of symptoms for ≤ 5 days
• Mild-mod symptoms not requiring hospitalization or oxygen due to COVID-19
• At least 1 underlying medical condition associated with increased risk of severe illness (>60 yo, active cancer, CKD, COPD, obesity, serious heart conditions, diabetes)

Allocation [TBD]

• Initial allocation/supply will be very limited and allocated to select pharmacies by State with LHD input
• Allocation is based on case count
  • Case count calculated as 14-day totals with a 7-day lag to ensure better accuracy

Last updated: 12/1/2021
CDC Strengthens Booster Recommendation

- With recent emergence of Omicron variant, CDC now recommends everyone 18+ should get a booster shot:
  - 6 months after initial Pfizer or Moderna series, or
  - 2 months after initial J&J vaccine

- Useful Resources
  - CDC Expands COVID-19 Booster Recommendations
  - CDPH Fact Sheet: Omicron Variant (ca.gov)
## CDC Strengthens Booster Recommendation

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Eligibility</th>
<th>Dose</th>
<th>Interval</th>
<th>Status</th>
</tr>
</thead>
</table>
| Pfizer       | • 18 years and older | 0.3 mL (30 ug) [same as primary series] | At least 6 months after the primary series | • FDA Authorized  
• CDC Recommended |
| Moderna      | 0.25 mL (50 ug) [half the dose of the primary series] | At least **2 months** after the initial dose |  |
| Janssen      | 0.5 mL [same as initial dose] |  |  |  |

The CDC now recommends that all 18+ yo *should* receive a booster dose.
Boosters/Additional Doses for People Vaccinated Outside the U.S.

People who have completed **all recommended doses** of a **WHO-authorized but not FDA approved/authorized vaccine†** or **heterologous series (FDA approved/authorized + WHO-authorized)** are eligible for an additional and/or booster dose.

### Additional Dose
- **Eligibility:** 12+ yo, moderately to severely immunocompromised
- **Interval:** ≥28 days after primary series
- **Product:** Pfizer 30 ug (12+yo formulation)

### Booster Dose
- **Eligibility:** 18+ yo
- **Interval:** ≥6 months after primary series
- **Product:** Pfizer 30 ug (12+yo formulation)

People who have received only the first dose of a WHO-authorized vaccine, or received all or some of a non-WHO authorized vaccine, and are re-vaccinated with an FDA-approved/authorized vaccine series are **not recommended** to receive an additional or booster dose at this time.

---

† For complete list visit https://www.who.int/teams/regulation-prequalification/eul/covid-19
Allocation schedule remains inconsistent and does not appear to be released on a weekly cadence.
myCAvax Vaccine Ordering

Vaccine Order Type

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Order Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pediatric Pfizer (5-11)</td>
<td>Small Orders*</td>
</tr>
<tr>
<td>Pfizer (12+)</td>
<td></td>
</tr>
<tr>
<td>Moderna</td>
<td>Small Orders, or Standard Orders (MOQ: 100 doses)</td>
</tr>
<tr>
<td>Janssen</td>
<td></td>
</tr>
</tbody>
</table>

*Place all Pfizer orders using small orders feature, unless:
- Can utilize minimum order quantities
  - Pfizer: 1,170 doses
  - Pediatric Pfizer: 100 doses
- Understand handling of dry ice

Standard orders placed by Monday, generally have a 1-week turnaround time (delivery cadence)
Storage & Handling Updates
Recently redistributed, now expired, LOTs:
- EW0185
- EW0187

Check vials for **printed** expiry date of August 2021 (which were extended to November 2021)
1. Dispose of vaccine as regulated medical waste, in pharmaceutical waste container or comingled pharmaceutical/sharps waste container
2. Report expired doses on myCAvax
Moderna 10 dose/vial Back in Stock!

- Moderna-14 has been discontinued
- New orders will be fulfilled with Moderna-10
  - Keep Moderna-14 and Moderna-10 inventory separate if you stock both formulations

- Regardless of 10-dose or 14-dose formulation, may only puncture vials a maximum of 20 times
Syringe Size FAQs

- **Can we use syringes without a .25mL graduation to draw up Moderna boosters?**
  - CDPH advises providers that when using syringes that have tick marks at 0.2 mL intervals, they should use their best judgment to draw up half-way between the tick marks to extract the proper volume. For example, Moderna booster vaccine should be drawn to between 0.24mL and 0.26mL.

- **Can we dilute Pfizer Pediatric (5-11 Years) vaccine with the 5mL syringes?**
  - CDPH: If you have syringes with smaller graduations, you are welcome to use them.
  - CDC: "Pfizer recommends the use of a syringe with appropriate graduations to dilute with the directed 1.3mL of saline. The impact to the final dose with a 1.2 or 1.4mL dilution volume would be within 4% of the target dose. This suggests that using a syringe with 0.2mL graduations and estimating the 1.3mL volume will not significantly impact the intended dose."
  - Pfizer: The dose would still round to 10µg (10.4µg to 9.6µg)
Coming Soon: COMIRNATY

- The branded COMIRANTY for 12+ year olds [gray top] will be phased in late December/January

- Pfizer 12+ [purple top] formulation will be retired over the same timeframe

- COMIRNATY does not require dilution

For more information, please see the COMIRNATY EUA Fact Sheet Available Here
Temperature Excursion Resources

- Moderna Temperature Excursion Tool: Link
- Janssen Stability Information: Link
- Pfizer
  - Medical Information Digital Assistant: Link
  - Before Dilution: Link
  - After Dilution: Link

- Please continue to report excursions on myCAvax
Other Resources
Meetings now held on Zoom
Fridays – 9:00AM to 10:00AM

Meeting Link: Click here
Session Password: Immunize!

View archived sessions at: https://eziz.org/covid/

No Provider Office Hours on:
• December 24
• December 31
Provider Resources on EZIZ.org/COVID

Updates for Providers

- COVID-19 Vaccination Program FAQs (Updated 11/18)
- Connect with Vaccine Experts – Provider Office Hours Every Monday
- Worksite Training
- Weekly webinars and Training Calendar

Alerts

Adjusted Delivery Schedule for Thanksgiving Closure
- Holiday Delivery Calendar

Boosters
- Booster to Anyone 16 Years and Older
- Booster Vaccine Eligibility (Provider Readiness Checklist)
- Clinical Considerations for People Who Received COVID-19 Vaccine Outside the US

Vaccination of 5 to 11-Year-Olds:
- CPG Clinical Summary for Pfizer Vaccine in Children 5-11 Years
- View Recent Town Hall with Dr. Erica Peer: Archived Webinar | Slides

Tools to Avoid Vaccine Mix-Ups:
- Comparison Guide of COVID-19 Vaccine Products
- COVID-19 Vaccine Eligibility Chart | Summary of Related Guidance and Requirements
- Vaccine Administration Checklist
- Preventing Administration Errors
- Co-administration Tips

Now Enrolling Providers of Pediatric Services
- Benefits for Primary Care Providers
- Find Information on How to Enroll
- Apply for Grants Up to $53,000 for Support of Small Practices. Ends Dec. 17

Featured Resources

Vaccine Management:
- Reporting Doses Spilled, Expired, or Wasted (Including Moderna booster doses)
- Ordering Vaccines | Ordering & Distribution Database
- Receiving Redistributed Small Orders
- Vaccine Management Checklist
- Ancillary Kit Configuration Tool (Helps calculate number of items to pack for number of doses being redistributed)
Thank you!

Questions? Email us at: vaccinebranch@eoc.sccgov.org